SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 Rheumatoid Arthritis Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 256981.
  • 2
    Funovits J, Aletaha D, Bykerk V, Combe B, Dougados M, Emery P, et al. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report Phase 1. Ann Rheum Dis 2010; 69: 158995.
  • 3
    Hansen P, Ombler F. A new method for scoring multi-attribute value models using pairwise rankings of alternatives. J Multi-Crit Decis Anal 2009; 15: 87107.
  • 4
    De Coster C, Noseworthy T. Improving wait times in the referral-consultation process: WCWL priority referral scores. Proceeding of the Taming of the Queue VI Conference, Canadian Policy Research Networks. 2009 Mar 27–28; Ottawa, Ontario, Canada.
  • 5
    De Coster C, Fitzgerald A, Noseworthy T. Developing priority-setting referral tools for medical sub-specialities. Proceedings of the Annual Canadian Association for Health Services and Policy Research Conference. 2008 May 26–28; Gatineau, Quebec, Canada.
  • 6
    Fitzgerald A, De Coster C, Naden R, Noseworthy T, Western Canada Wait List Project Rheumatology Clinical Panel. Priority-setting for referrals from primary case physicians to rheumatologists [abstract]. Arthritis Rheum 2008; 58 Suppl: S884.
  • 7
    Naden R, Paterson R, Hansen P, Barber A, Ombler F, Stewart R, et al. Assigning clinical priority: a systematic methodology. Proceedings of the 6th International Conference on Priorities in Health Care, International Health Economics Association. 2006 Sep 20–22; Toronto, Ontario, Canada.
  • 8
    Barber A, Doolan Noble F, Stewart R, Wilkins G, Naden R, North D. Prioritisation for coronary artery bypass surgery: can the process be improved? Proceedings of the 5th International Conference on Priorities in Health Care, International Health Economics Association. 2004 Nov 3–5; Wellington, New Zealand.
  • 9
    Aggarwal R, Liao K, Nair R, Ringold S, Costenbader KH. Anti–citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis [review]. Arthritis Rheum 2009; 61: 147283.
  • 10
    Van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, et al. Value of anti–modified citrullinated vimentin and third-generation anti–cyclic citrullinated peptide compared with second-generation anti–cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 2009; 60: 223241.
  • 11
    Mjaavatten MD, van der Hiejde DM, Uhlig T, Haugen AJ, Nygaard H, Sidenvall G, et al. Levels of anti-CCP and IgM RF predict persistent arthritis in patients with very early undifferentiated arthritis (UA) [abstract]. Arthritis Rheum 2009; 60 Suppl: S123.
  • 12
    Van Gaalen FA, Visser H, Huizinga TW. A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis. Ann Rheum Dis 2005; 64: 15102.